Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines

Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines

NH36 is a vital enzyme of the DNA metabolism and a specific target for anti-Leishmania chemotherapy. We developed second-generation vaccines composed of the FML complex or its main native antigen, the NH36 nucleoside hydrolase of Leishmania (L.) donovani and saponin, and a DNA vaccine containing the...

Full description

Bibliographic Details
Main Author:	Clarisa Beatriz Palatnik-de-Sousa
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-04-01
Series:	Frontiers in Immunology
Subjects:	visceral leishmaniasis vaccines cutaneous leishmaniasis vaccines nucleoside hydrolases multi-epitope vaccines Leishmune® vaccine
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2019.00813/full

Similar Items

Leishmania donovani Nucleoside Hydrolase terminal domains in cross-protective immunotherapy against Leishmania amazonensis murine infection
by: Dirlei eNico, et al.
Published: (2014-06-01)

F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis
by: Eugenia Carrillo, et al.
Published: (2017-07-01)

Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+-epitopes of Leishmania donovani Nucleoside Hydrolase terminal domains
by: Dirlei eNico, et al.
Published: (2014-05-01)

Vaccines for canine leishmaniasis
by: Clarisa B. Palatnik-De-Sousa
Published: (2012-04-01)

The F1F3 Recombinant Chimera of Leishmania donovani-Nucleoside Hydrolase (NH36) and Its Epitopes Induce Cross-Protection Against Leishmania (V.) braziliensis Infection in Mice
by: Marcus Vinícius Alves-Silva, et al.
Published: (2019-04-01)

Editorial: Epitope Discovery and Synthetic Vaccine Design
by: Clarisa Beatriz Palatnik-de-Sousa, et al.
Published: (2018-04-01)

A combination DNA vaccine encoding nucleoside hydrolase 36 and glycoproteine 63 protects female but not male hamsters against Leishmania mexicana
by: Chalé-balboa W.G., et al.
Published: (2009-09-01)

NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis
by: Dirlei Nico, et al.
Published: (2018-05-01)

The Delay in the Licensing of Protozoal Vaccines: A Comparative History
by: Clarisa Beatriz Palatnik-de-Sousa, et al.
Published: (2020-03-01)

Vaccination with Formulation of Nanoparticles Loaded with <i>Leishmania amazonensis</i> Antigens Confers Protection against Experimental Visceral Leishmaniasis in Hamster
by: Marco Antonio Cabrera González, et al.
Published: (2023-01-01)

Leishmania infantum Virulence Factor A2 Protein: Linear B-Cell Epitope Mapping and Identification of Three Main Linear B-Cell Epitopes in Vaccinated and Naturally Infected Dogs
by: Monique Paiva Campos, et al.
Published: (2018-07-01)

Corrigendum: Leishmania infantum Virulence Factor A2 Protein: Linear B-Cell Epitope Mapping and Identification of Three Main Linear B-Cell Epitopes in Vaccinated and Naturally Infected Dogs
by: Monique Paiva Campos, et al.
Published: (2018-10-01)

A New Strategy for Mapping Epitopes of LACK and PEPCK Proteins of <i>Leishmania amazonensis</i> Specific for Major Histocompatibility Complex Class I
by: Edlainne Pinheiro Ferreira-Sena, et al.
Published: (2023-03-01)

In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani
by: Subhadip Saha, et al.
Published: (2022-08-01)

A current perspective on leishmaniasis
by: Angela Clem
Published: (2010-01-01)

A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against <i>Leishmania infantum</i> Infection
by: Daniela P. Lage, et al.
Published: (2022-07-01)

Phase I and II Clinical Trial Comparing the LBSap, Leishmune<sup>®</sup>, and Leish-Tec<sup>®</sup> Vaccines against Canine Visceral Leishmaniasis
by: Rodrigo Dian de Oliveira Aguiar-Soares, et al.
Published: (2020-11-01)

Transmission-Blocking Vaccines for Canine Visceral Leishmaniasis: New Progress and Yet New Challenges
by: Jaqueline Costa Leite, et al.
Published: (2023-10-01)

Vaccinomics-based next-generation multi-epitope chimeric vaccine models prediction against Leishmania tropica - a hierarchical subtractive proteomics and immunoinformatics approach
by: Sara Aiman, et al.
Published: (2023-09-01)

Visceral Leishmaniasis: Advancements in vaccine development via classical and molecular approaches
by: Sumit eJoshi, et al.
Published: (2014-08-01)

Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice
by: Omid Chavoshian, et al.
Published: (2013-09-01)

Comparison of Protective Potency of DNA and Live Vaccines Expressing A2-CPA-CPB-CTE Antigens against Visceral Leish-maniasis in Syrian Hamster as Preliminary Study
by: Yasaman TASLIMI, et al.
Published: (2020-09-01)

Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis
by: Olugbenga Samson Onile, et al.
Published: (2022-09-01)

New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine
by: Diana Souza de Oliveira, et al.
Published: (2024-03-01)

Design of a Chimeric Multi-Epitope Vaccine (CMEV) against Both <i>Leishmania martiniquensis</i> and <i>Leishmania orientalis</i> Parasites Using Immunoinformatic Approaches
by: Kentaro Imaizumi, et al.
Published: (2022-10-01)

Sirolimus enhances the protection achieved by a DNA vaccine against Leishmania infantum
by: Alba Martínez-Flórez, et al.
Published: (2020-06-01)

Immunoinformatics Approach to Design a Multi-Epitope Nanovaccine against <i>Leishmania</i> Parasite: Elicitation of Cellular Immune Responses
by: Maritsa Margaroni, et al.
Published: (2023-01-01)

Can vaccines against canine visceral leishmaniasis interfere with the serological diagnostics recommended by the Brazilian Ministry of Health?
by: Monique Paiva de Campos, et al.

What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist
by: Clarisa B. Palatnik-de-Sousa, et al.
Published: (2020-08-01)

Peptide Vaccines for Leishmaniasis
by: Rory C. F. De Brito, et al.
Published: (2018-05-01)

The History of Live Attenuated <i>Centrin</i> Gene-Deleted <i>Leishmania</i> Vaccine Candidates
by: Greta Volpedo, et al.
Published: (2022-04-01)

Immunization with <i>centrin</i>-Deficient <i>Leishmania braziliensis</i> Does Not Protect against Homologous Challenge
by: Francys Avendaño-Rangel, et al.
Published: (2024-03-01)

Characterization and speculations on the urbanization of visceral leishmaniasis in Brazil Caracterização e especulações acerca da urbanização da leishmaniose visceral no Brasil
by: Carlos Henrique Nery Costa
Published: (2008-12-01)

Live vaccination tactics: possible approaches for controlling visceral leishmaniasis
by: Noushin eSaljoughian, et al.
Published: (2014-03-01)

Current Approaches to Develop a Live Vaccine against Leishmania majo
by: Farshid Yeganeh, et al.
Published: (2017-06-01)

An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes
by: Md Anik Ashfaq Khan, et al.
Published: (2020-04-01)

Prediction of an immunogenic peptide ensemble and multi-subunit vaccine for Visceral leishmaniasis using bioinformatics approaches
by: Manu Kupani, et al.
Published: (2023-12-01)

Polymeric Delivery Systems as a Potential Vaccine against Visceral Leishmaniasis: Formulation Development and Immunogenicity
by: João Guilherme Lino da Silva, et al.
Published: (2023-07-01)

Theranostic applications of phage display to control leishmaniasis: selection of biomarkers for serodiagnostics, vaccination, and immunotherapy
by: Eduardo Antonio Ferraz Coelho, et al.
Published: (2015-08-01)

Immunisation with Transgenic <i>L. tarentolae</i> Expressing Gamma Glutamyl Cysteine Synthetase from Pathogenic <i>Leishmania</i> Species Protected against <i>L. major</i> and <i>L. donovani</i> Infection in a Murine Model
by: Derya Topuz Ata, et al.
Published: (2023-05-01)